Tuberculosis, which kills more than one person every 20 seconds, is
much harder to detect in children than in adults because they do not
always show the typical symptoms, such as coughing, night sweats and
blood in the phlegm or spit.
As a result, health workers tend to focus on treating adults
displaying symptoms of the potentially deadly air-borne disease,
experts said. But, if left untreated, children with TB become ill
and die much faster than adults.
"A huge number of children are suffering and dying from TB because
the majority of efforts to fight the disease have focused on adults,
so children with TB have become invisible," said Mercedes Becerra,
an associate professor at Harvard Medical School in Boston, United
States.
"And even if they get treatment, we lack reliable diagnostic tools
and child-friendly medicines, which hinders effective treatment and
can even fuel drug resistance," she told the Thomson Reuters
Foundation in a telephone interview.
TB, which kills at least 80,000 children each year, is a contagious
bacterial lung illness that spreads via the coughs and sneezes of an
infected person.
It is hard to treat, requiring months of antibiotic treatment, and
drug resistant strains are rapidly gaining a foothold.
SLOW PROGRESS
Five years ago the WHO recommended new and more appropriate doses
for childhood TB but pills for children have yet to be manufactured.
Instead, doctors and parents have to crush or split adult pills,
which often leads to the wrong doses, potentially fuelling a growing
number of drug-resistant cases that no longer respond to the most
commonly used treatments for TB, experts said.
As many as 32,000 children become sick with multi-drug resistant
strain of TB (MDR-TB) each year, according to a study last year
co-authored by Becerra, forcing them to take a daily cocktail of
drugs with heavy side effects for up to two years.
"Even if children get ill with MDR-TB, they respond well if they get
treatment," said Becerra. "(Not treating them) is a huge missed
opportunity - if you treat them, you can cure them."
Shelly Malhotra, director of market access at the TB Alliance, said
progress in creating child-friendly TB drugs had been slow but that
three pharmaceutical companies were currently seeking approval from
the WHO to produce such formulations.
The New York-based TB Alliance, which is dedicated to the discovery
and development of new, faster-acting and affordable TB medicines,
is hoping to make them available through its Global Drug Facility in
the second half of this year, she said.
[to top of second column] |
The lack of child-friendly formulations is part of a wider malaise
in finding new TB drugs, an issue that has become more pressing due
to drug resistance.
Even though TB is the world's second largest infectious disease,
there have been no new drugs for almost 50 years and new ones
developed recently are still undergoing trials.
LACK OF DATA
Manufacturers have been slow to respond to the challenge of finding
child-friendly TB drugs partly because a lack of accurate data makes
it hard for them to gauge the size of their potential market,
Malhotra said.
"There is a lack of accurate data in many countries, in particular
where there is a large private treatment sector, so we don't get
good data from villages, from the private providers, or even
hospitals," Malhotra told the Thomson Reuters Foundation.
Every childhood TB case should be registered with the national TB
control program, including crucial data such as age, HIV status and
treatment outcome, she said.
Becerra urged governments and donors to provide more funding so that
health workers could get better training to make sure they do not
miss children with TB.
Simple steps, such as making sure that children of TB patients are
tested for the disease, can go a long way to improve the situation,
said Becerra.
"TB is a family disease, a social disease, so that's where it needs
to be tackled - at the household level through contact-tracing," she
said.
"It's a fundamental part of what Europe and the U.S. have done for a
long time but it's still not done consistently in the developing
world due to lack of resources."
(Reporting By Astrid Zweynert)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |